Skip to content

Adult Bipolar Mania

An International, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium Versus Placebo as an Add on to SEROQUEL XR (Quetiapine Fumarate) in Adult Patients With Acute Mania

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00931723
Enrollment
356
Registered
2009-07-02
Start date
2009-06-30
Completion date
2010-11-30
Last updated
2012-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Mania

Keywords

Acute Mania, Mania, Adults, Seroquel, Acute Mania in Adult Patients

Brief summary

The purpose of this study is to determine if lithium 600-1800 mg/day is effective when added to quetiapine fumarate extended release (quetiapine XR or SEROQUEL® XR) 400-800 mg/day in treating acute mania and if so, how it compares with placebo (a non-active capsule, like a sugar pill, that looks like lithium).

Interventions

Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.

DRUGLithium

Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.

DRUGPlacebo

Oral treatment twice daily.

Sponsors

Quintiles, Inc.
CollaboratorINDUSTRY
AstraZeneca
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Provision of informed consent before any study procedures are performed. * The patient must have a documented clinical diagnosis for bipolar I disorder, including recent episode manic or mixed, and being male of females age 18-65 years, inclusive. * Patients may be outpatients or inpatients at enrollment visit, but all patients must be inpatients when randomized and remain inpatients until discharged at the discretion of the investigator.

Exclusion criteria

* The patient can not have had up to 8 mood episodes during the past 12 months and not been continuously hospitalized for acute bipolar for up to 3 weeks immediately before participating in the study. * The patient can not have a past diagnosis of stroke or medically documented transient ischemic attacks (TIA) or a history of seizure disorder, except for febrile convulsions. * The patient must not have received electroconvulsive treatment (ECT) within 90 days before participating in the study and in the doctors judgement pose a current suicidal or homicidal risk.

Design outcomes

Primary

MeasureTime frameDescription
Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43)Change in YMRS total score from baseline to Day 43.The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).

Secondary

MeasureTime frameDescription
RemissionDays 8 to 43The number of patients with clinically significant remission (defined as YMRS total score ≤12) from Days 8 to 43) was calculated. The Young Mania Rating Scale total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).
Change From Baseline to Day 43 in CGI-BP-S (Clinical Global Impressions for Bipolar Disorder-Severity of Illness)Change from baseline to Day 43.The CGI-BP-S scale rates the severity of the patient's illness at the time of assessment and is scored from 1 to 7 (1=normal, not ill to 7=very severely ill). Higher CGI-BP-S scores indicate greater illness severity.
Change From Baseline to Day 43 in CGI-BP-C (Clinical Global Impressions for Bipolar Disorder-Change From Preceding Phase)Change from baseline to Day 43The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores \>4 indicate worsening, while scores \<4 indicate improvement.
Improvement of Overall Bipolar IllnessDay 43.The number of patients with a CGI-BP-C of Much or Very much improved in overall bipolar illness assessment at Day 43 was calculated. The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores \>4 indicate worsening, while scores \<4 indicate improvement.
Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total ScoreChange from baseline to Day 43.The MADRS is a 10-item scale that evaluates depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. Higher MADRS scores indicate higher levels of depressive symptoms.
Change From Baseline to Day 43 in Positive and Negative Syndrome Scale (PANSS) Total ScoreChange from baseline to Day 43The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 individual-item scores and ranges from 30 to 210.A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Change From Baseline to Day 43 in PANSS Activation Subscale ScoreChange from baseline to Day 43The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS activation subscale score for effect on agitation and aggression is the sum of 6 PANSS individual items (ie, hostility, poor impulse control, excitement, uncooperativeness, poor rapport and tension) and ranges from 6 to 42. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Change From Baseline to Day 43 in PANSS Positive Subscale ScoreChange from baseline to Day 43The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS positive subscale score is the sum of the 7 positive item scores (ie, delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility) and ranges from 7 to 49. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Change From Baseline to Day 43 in Each YMRS Item Score No. 1Change from baseline to Day 43The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 1 (Elevated mood) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
The Number of Patients With Clinically Significant Response.43 days (from baseline to Day 43)The number of patients with clinically significant response (defined as ≥50% reduction from baseline to Day 43 in the YMRS total score) was calculated. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms.
Change From Baseline to Day 43 in Each YMRS Item Score No. 3Change from baseline to Day 43The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 3 (sexual interest) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Change From Baseline to Day 43 in Each YMRS Item Score No. 4Change from baseline to Day 43The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 4 (sleep) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Change From Baseline to Day 43 in Each YMRS Item Score No. 5Change from baseline to Day 43The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 5 (Irritability) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Change From Baseline to Day 43 in Each YMRS Item Score No. 6Change from baseline to Day 43The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 6 (speech-rate and amount) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Change From Baseline to Day 43 in Each YMRS Item Score No. 7Change from baseline to Day 43The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 7 (language-thought disorder) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Change From Baseline to Day 43 in Each YMRS Item Score No. 8Change from baseline to Day 43The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 8 (content) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Change From Baseline to Day 43 in Each YMRS Item Score No. 9Change from baseline to Day 43The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. . This analysis is for Item 9 (disruptive-aggressive behavior) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Change From Baseline to Day 43 in Each YMRS Item Score No. 10Change from baseline to Day 43The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 10 (appearance) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Change From Baseline to Day 43 in Each YMRS Item Score No. 11Change from baseline to Day 43The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 11 (insight) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Change From Baseline to Day 43 in Each YMRS Item Score No. 2Change from baseline to Day 43The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 2 (increased motor activity-energy) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Countries

Belgium, Bulgaria, Germany, India, Israel, Poland, Russia, South Africa, Ukraine

Participant flow

Recruitment details

This multicenter study was conducted between 24 June 2009 and 22 November 2010.

Pre-assignment details

The study had an up to 28-day enrollment period (including a washout period lasting 7 to 28 days) and a 6-week double-blind treatment period. Patients were randomized to receive lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day or placebo+quetiapine XR 400 to 800 mg/day.

Participants by arm

ArmCount
Lithium+Quetiapine XR
Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day
173
Placebo+Quetiapine XR
Placebo+quetiapine XR 400 to 800 mg/day
183
Total356

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event613
Overall StudyCondition under investigation worsened12
Overall StudyLack or insufficient theraputic response25
Overall StudyLate hospital discharge10
Overall StudyLithium found in blood01
Overall StudyLost to Follow-up12
Overall StudySafety reasons01
Overall StudySevere non-compliance to protocol20
Overall StudySponsor decision10
Overall StudyStudy-specific discontinuation criteria11
Overall StudyTook prohibited concomitant medication01
Overall StudyWithdrawal by Subject1113

Baseline characteristics

CharacteristicLithium+Quetiapine XRPlacebo+Quetiapine XRTotal
Age Continuous37.9 Years
STANDARD_DEVIATION 12.71
38.8 Years
STANDARD_DEVIATION 12.09
38.3 Years
STANDARD_DEVIATION 12.39
Sex: Female, Male
Female
72 Participants62 Participants134 Participants
Sex: Female, Male
Male
101 Participants121 Participants222 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
106 / 17383 / 183
serious
Total, serious adverse events
4 / 1738 / 183

Outcome results

Primary

Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43)

The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).

Time frame: Change in YMRS total score from baseline to Day 43.

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43)-22.8 Scores on a scaleStandard Error 0.706
Placebo+Quetiapine XRChange in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43)-20.1 Scores on a scaleStandard Error 0.711
Secondary

Change From Baseline to Day 43 in CGI-BP-C (Clinical Global Impressions for Bipolar Disorder-Change From Preceding Phase)

The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores \>4 indicate worsening, while scores \<4 indicate improvement.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in CGI-BP-C (Clinical Global Impressions for Bipolar Disorder-Change From Preceding Phase)1.7 Scores on a scaleStandard Error 0.085
Placebo+Quetiapine XRChange From Baseline to Day 43 in CGI-BP-C (Clinical Global Impressions for Bipolar Disorder-Change From Preceding Phase)1.9 Scores on a scaleStandard Error 0.086
Secondary

Change From Baseline to Day 43 in CGI-BP-S (Clinical Global Impressions for Bipolar Disorder-Severity of Illness)

The CGI-BP-S scale rates the severity of the patient's illness at the time of assessment and is scored from 1 to 7 (1=normal, not ill to 7=very severely ill). Higher CGI-BP-S scores indicate greater illness severity.

Time frame: Change from baseline to Day 43.

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in CGI-BP-S (Clinical Global Impressions for Bipolar Disorder-Severity of Illness)-2.5 Scores on a scaleStandard Error 0.079
Placebo+Quetiapine XRChange From Baseline to Day 43 in CGI-BP-S (Clinical Global Impressions for Bipolar Disorder-Severity of Illness)-2.2 Scores on a scaleStandard Error 0.08
Secondary

Change From Baseline to Day 43 in Each YMRS Item Score No. 1

The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 1 (Elevated mood) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 1-1.8 Scores on a scaleStandard Error 0.079
Placebo+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 1-1.6 Scores on a scaleStandard Error 0.08
Secondary

Change From Baseline to Day 43 in Each YMRS Item Score No. 10

The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 10 (appearance) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 10-1.1 Scores on a scaleStandard Error 0.057
Placebo+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 10-1.0 Scores on a scaleStandard Error 0.057
Secondary

Change From Baseline to Day 43 in Each YMRS Item Score No. 11

The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 11 (insight) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 11-1.4 Scores on a scaleStandard Error 0.069
Placebo+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 11-1.2 Scores on a scaleStandard Error 0.07
Secondary

Change From Baseline to Day 43 in Each YMRS Item Score No. 2

The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 2 (increased motor activity-energy) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 2-1.9 Scores on a scaleStandard Error 0.071
Placebo+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 2-1.7 Scores on a scaleStandard Error 0.072
Secondary

Change From Baseline to Day 43 in Each YMRS Item Score No. 3

The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 3 (sexual interest) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 3-1.3 Scores on a scaleStandard Error 0.063
Placebo+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 3-1.1 Scores on a scaleStandard Error 0.064
Secondary

Change From Baseline to Day 43 in Each YMRS Item Score No. 4

The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 4 (sleep) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 4-2.0 Scores on a scaleStandard Error 0.085
Placebo+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 4-1.8 Scores on a scaleStandard Error 0.086
Secondary

Change From Baseline to Day 43 in Each YMRS Item Score No. 5

The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 5 (Irritability) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 5-3.1 Scores on a scaleStandard Error 0.109
Placebo+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 5-2.8 Scores on a scaleStandard Error 0.11
Secondary

Change From Baseline to Day 43 in Each YMRS Item Score No. 6

The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 6 (speech-rate and amount) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 6-3.1 Scores on a scaleStandard Error 0.116
Placebo+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 6-2.9 Scores on a scaleStandard Error 0.118
Secondary

Change From Baseline to Day 43 in Each YMRS Item Score No. 7

The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 7 (language-thought disorder) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 7-1.5 Scores on a scaleStandard Error 0.071
Placebo+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 7-1.4 Scores on a scaleStandard Error 0.072
Secondary

Change From Baseline to Day 43 in Each YMRS Item Score No. 8

The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 8 (content) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 8-3.1 Scores on a scaleStandard Error 0.132
Placebo+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 8-2.9 Scores on a scaleStandard Error 0.133
Secondary

Change From Baseline to Day 43 in Each YMRS Item Score No. 9

The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. . This analysis is for Item 9 (disruptive-aggressive behavior) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 9-2.5 Scores on a scaleStandard Error 0.088
Placebo+Quetiapine XRChange From Baseline to Day 43 in Each YMRS Item Score No. 9-2.1 Scores on a scaleStandard Error 0.089
Secondary

Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The MADRS is a 10-item scale that evaluates depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. Higher MADRS scores indicate higher levels of depressive symptoms.

Time frame: Change from baseline to Day 43.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-4.8 Scores on a scaleStandard Error 0.366
Placebo+Quetiapine XRChange From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-4.1 Scores on a scaleStandard Error 0.368
Secondary

Change From Baseline to Day 43 in PANSS Activation Subscale Score

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS activation subscale score for effect on agitation and aggression is the sum of 6 PANSS individual items (ie, hostility, poor impulse control, excitement, uncooperativeness, poor rapport and tension) and ranges from 6 to 42. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in PANSS Activation Subscale Score-7.1 Scores on a scaleStandard Error 0.281
Placebo+Quetiapine XRChange From Baseline to Day 43 in PANSS Activation Subscale Score-5.9 Scores on a scaleStandard Error 0.283
Secondary

Change From Baseline to Day 43 in PANSS Positive Subscale Score

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS positive subscale score is the sum of the 7 positive item scores (ie, delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility) and ranges from 7 to 49. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in PANSS Positive Subscale Score-8.1 Scores on a scaleStandard Error 0.316
Placebo+Quetiapine XRChange From Baseline to Day 43 in PANSS Positive Subscale Score-7.0 Scores on a scaleStandard Error 0.316
Secondary

Change From Baseline to Day 43 in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 individual-item scores and ranges from 30 to 210.A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame: Change from baseline to Day 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Lithium+Quetiapine XRChange From Baseline to Day 43 in Positive and Negative Syndrome Scale (PANSS) Total Score-19.2 Scores on a scaleStandard Error 0.914
Placebo+Quetiapine XRChange From Baseline to Day 43 in Positive and Negative Syndrome Scale (PANSS) Total Score-15.6 Scores on a scaleStandard Error 0.914
Secondary

Improvement of Overall Bipolar Illness

The number of patients with a CGI-BP-C of Much or Very much improved in overall bipolar illness assessment at Day 43 was calculated. The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores \>4 indicate worsening, while scores \<4 indicate improvement.

Time frame: Day 43.

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (NUMBER)
Lithium+Quetiapine XRImprovement of Overall Bipolar Illness134 Participants
Placebo+Quetiapine XRImprovement of Overall Bipolar Illness125 Participants
Secondary

Remission

The number of patients with clinically significant remission (defined as YMRS total score ≤12) from Days 8 to 43) was calculated. The Young Mania Rating Scale total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).

Time frame: Days 8 to 43

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (NUMBER)
Lithium+Quetiapine XRRemission125 Participants
Placebo+Quetiapine XRRemission105 Participants
Secondary

The Number of Patients With Clinically Significant Response.

The number of patients with clinically significant response (defined as ≥50% reduction from baseline to Day 43 in the YMRS total score) was calculated. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms.

Time frame: 43 days (from baseline to Day 43)

Population: 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

ArmMeasureValue (NUMBER)
Lithium+Quetiapine XRThe Number of Patients With Clinically Significant Response.137 Participants
Placebo+Quetiapine XRThe Number of Patients With Clinically Significant Response.120 Participants

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026